NAMPT and obesity due to melanocortin 4 receptor deficiency: Emerging evidences in recent decades have shown increased levels of visfatin in overweight/obesity, type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases and cancers [45, 49–51].